Validation and simplification of the radiation therapy oncology group recursive partitioning analysis classification for glioblastoma

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 3, 2011, Pages 623-630

  Li, Jing ^a   Wang, Meihua ^b   Won, Minhee ^b   Shaw, Edward G ^c   Coughlin, Christopher ^d   Curran Jr , Walter J ^e   Mehta, Minesh P ^f  

^a UNIVERSITY OF TEXAS   (United States)

^b RTOG Statistical Center   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d FEDERAL BUREAU OF PRISONS   (United States)

^e EMORY CLINIC   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Glioblastoma; Prognostic factors; Recursive partitioning analysis; RTOG

Indexed keywords

ANAPLASTIC ASTROCYTOMA; CARMUSTINE; DATA SETS; GLIOBLASTOMA MULTIFORME; GLIOBLASTOMAS; MALIGNANT GLIOMA; MEDIAN SURVIVAL TIME; NEUROLOGIC FUNCTION; NEW MODEL; ORIGINAL MODEL; PERFORMANCE STATUS; PROGNOSTIC FACTORS; RADIATION DOSE; RADIATION THERAPY ONCOLOGY GROUPS; RECURSIVE PARTITIONING ANALYSIS; RTOG; SIMPLIFIED MODELS;

DATABASE SYSTEMS; DOSIMETRY; ONCOLOGY; RADIOTHERAPY; REGRESSION ANALYSIS; STATISTICAL TESTS; TUMORS;

RADIATION;

AZIRIDINYLBENZOQUINONE; CARMUSTINE; MISONIDAZOLE; NITROSOUREA; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; BRAIN DYSFUNCTION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DATA BASE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; PAPILLEDEMA; PRIORITY JOURNAL; RACE; RADIATION DOSE; SENSORY DYSFUNCTION; SOMNOLENCE; VALIDATION STUDY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DECISION TREES; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PROGNOSIS; RADIOTHERAPY DOSAGE; YOUNG ADULT;

EID: 80053613758     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.06.012     Document Type: Article

References (42)

1. M.D. Walker, S.B. Green, and D.P. Byar Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N Engl J Med 303 1980 1323 1329 (Pubitemid 11194457)
2. N. Laperriere, L. Zuraw, and G. Cairncross Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review Radiother Oncol 64 2002 259 273 (Pubitemid 35254019)
3. J. Perry, N. Laperriere, and L. Zuraw Adjuvant chemotherapy for adults with malignant glioma: A systematic review Can J Neurol Sci 34 2007 402 410 (Pubitemid 350248266)
4. M. Deutsch, S.B. Green, and T.A. Strike Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma Int J Radiat Oncol Biol Phys 16 1989 1389 1396 (Pubitemid 19154320)
5. R.P. Dinapoli, L.D. Brown, and R.M. Arusell Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma J Clin Oncol 11 1993 1316 1321 (Pubitemid 23199136)
6. K. Kristiansen, S. Hagen, and T. Kollevold Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group Cancer 47 1981 649 652 (Pubitemid 11135858)
7. D.F. Nelson, M. Diener-West, and A.S. Weinstein A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study Int J Radiat Oncol Biol Phys 12 1986 1793 1800 (Pubitemid 17182219)
8. D.G. Payne, W.J. Simpson, and C. Keen Malignant astrocytoma: Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial Cancer 50 1982 2301 2306 (Pubitemid 13244164)
9. W.R. Shapiro, S.B. Green, and P.C. Burger Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001 J Neurosurg 71 1989 1 9 (Pubitemid 19196544)
10. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996 (Pubitemid 40349501)
11. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
12. W.J. Curran Jr., C.B. Scott, and J. Horton Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials J Natl Cancer Inst 85 1993 704 710 (Pubitemid 23133591)
13. C.B. Scott, C. Scarantino, and R. Urtasun Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06 Int J Radiat Oncol Biol Phys 40 1998 51 55 (Pubitemid 28027566)
14. C.H. Chang, J. Horton, and D. Schoenfeld Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study Cancer 52 1983 997 1007 (Pubitemid 13050763)
15. W.J. Curran Jr., C.B. Scott, and J. Horton Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials J Neurooncol 12 1992 219 227
16. M. Werner-Wasik, C.B. Scott, and D.F. Nelson Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02 Cancer 77 1996 1535 1543
17. C. Coughlin, C. Scott, and C. Langer Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients Int J Radiat Oncol Biol Phys 48 2000 1351 1358
18. Curran W, Scott C, Yung W, et al. No survival benefit of hyperfractionated radiotherapy (RT) to 72.0 Gy & carmustine versus standard RT & carmustine for malignant glioma patients: Preliminary results of RTOG 90-06 (abstract 1154). Proceedings of the American Society of Clinical Oncology, Philadelphia, PA, 1996.
19. L. Gordon, and R.A. Olshen Tree-structured survival analysis Cancer Treat Rep 69 1985 1065 1069
20. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J. Amer. Stat. Assoc 53 1958 457 481
21. R.L. Prentice, and P. Marek A qualitative discrepancy between censored data rank tests Biometrics 35 1979 861 867 (Pubitemid 10172932)
22. A. Ciampi, R. du Berger, and H.G. Taylor RECPAM: A computer program for recursive partition and amalgamation for survival data and other situations frequently occurring in biostatistics. III. Classification according to a multivariate construct. Application to data on Haemophilus influenzae type b meningitis Comput Methods Programs Biomed 36 1991 51 61
23. G. Hommel A stagewise rejective multiple test procdure based on a modified Bonferroni test Biometrika 75 1988 383 386
24. G. Hommel A comparisonof two modified Bonferroni procedures Biometrika 76 1989 624 625
25. E.L. Korn, and R. Simon Measures of explained variation for survival data Stat Med 9 1990 487 503 (Pubitemid 20235019)
26. B. Fisher, M. Won, and D. Macdonald Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group 9513 Int J Radiat Oncol Biol Phys 53 2002 980 986 (Pubitemid 34722645)
27. C.J. Langer, J. Ruffer, and H. Rhodes Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme Int J Radiat Oncol Biol Phys 51 2001 113 119 (Pubitemid 32758870)
28. K. Sultanem, H. Patrocinio, and C. Lambert The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: Preliminary results of a prospective trial Int J Radiat Oncol Biol Phys 58 2004 247 252 (Pubitemid 38010359)
29. K.R. Lamborn, S.M. Chang, and M.D. Prados Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis Neuro Oncol 6 2004 227 235 (Pubitemid 39136506)
30. J. Del Rowe, C. Scott, and M. Werner-Wasik Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme J Clin Oncol 18 2000 1254 1259 (Pubitemid 30159843)
31. R. Miralbell, F. Mornex, and R. Greiner Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: Report of European Organization for Research and Treatment of Cancer trial 22933 J Clin Oncol 17 1999 3143 3149 (Pubitemid 29470644)
32. J.N. Sarkaria, M.P. Mehta, and J.S. Loeffler Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 32 1995 931 941
33. G.M. Videtic, L.E. Gaspar, and L. Zamorano Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas Int J Radiat Oncol Biol Phys 45 1999 687 692 (Pubitemid 29462650)
34. G.M. Videtic, L.E. Gaspar, and L. Zamorano Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis Int J Radiat Oncol Biol Phys 51 2001 963 968 (Pubitemid 33028883)
35. R.O. Mirimanoff, T. Gorlia, and W. Mason Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial J Clin Oncol 24 2006 2563 2569 (Pubitemid 46630635)
36. T. Gorlia, M.J. van den Bent, and M.E. Hegi Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 Lancet Oncol 9 2008 29 38
37. L. Dang, D.W. White, and S. Gross Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
38. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell;17:225-234.
39. H. Yan, D.D. Bigner, and V. Velculescu Mutant metabolic enzymes are at the origin of gliomas Cancer Res 69 2009 9157 9159
40. H. Yan, D.W. Parsons, and G. Jin IDH1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773
41. D.W. Parsons, S. Jones, and X. Zhang An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
42. H.S. Phillips, S. Kharbanda, and R. Chen Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 2006 157 173 (Pubitemid 43357943)